Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity.

Abstract

Objectives: To evaluate the therapeutic efficacy and safety of spesolimab in pediatric GPP treatment.

Methods: We report a 10-year-old male pediatric patient with refractory Generalized Pustular Psoriasis (GPP), comorbid epilepsy, hyperactivity, hypoproteinaemia. The coexistence of IL36RN: c.115 + 6T > C homozygous mutation and c.227C > T(p.P76L) heterozygous variation may have worsened his disease phenotype.

Results: Spesolimab treatment achieved a complete and rapid response. Pustules, erythema, and scales cleared within a week.

Conclusions: Spesolimab is effective in treating pediatric GPP patients, and it is potential to be a clinical treatment strategy for pediatric GPP in the future.